Epstein-Barr virus-induced changes in B-lymphocyte gene expression

Journal of Virology

Volumn 76, Issue 20, 2002, Pages 10427-10436

  Carter, Kara L ^a   Cahir McFarland, Ellen ^a   Kieff, Elliott ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PYROXYLIN; RNA;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS LATENCY;

B-LYMPHOCYTES; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VIRUS LATENCY;

EID: 0036785575     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.20.10427-10436.2002     Document Type: Article

References (126)

1. Abu-Ghazaleh, R., J. Kabir, H. Jia, M. Lobo, and I. Zachary. 2001. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and antiapoptosis in endothelial cells. Biochem. J. 360:255-264.
2. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608.
3. Alizadeh, A., M. Eisen, R. E. Davis, C. Ma, H. Sabet, T. Tran, J. I. Powell, L. Yang, G. E. Marti, D. T. Moore, J. R. Hudson, Jr., W. C. Chan, T. Greiner, D. Weisenburger, J. O. Armitage, I. Lossos, R. Levy, D. Botstein, P. O. Brown, and L. M. Staudt. 1999. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Symp. Quant. Biol. 64:71-78.
4. Alizadeh, A. A., M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos, A. Rosenwald, J. C. Boldrick, H. Sabet, T. Tran, X. Yu, J. I. Powell, L. Yang, G. E. Marti, T. Moore, J. Hudson, Jr., L. Lu, D. B. Lewis, R. Tibshirani, G. Sherlock, W. C. Chan, T. C. Greiner, D. D. Weisenburger, J. O. Armitage, R. Warnke, L. M. Staudt, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
5. Andersson, U., O. Martinez-Maza, J. Andersson, S. Britton, H. Gadler, M. De Ley, and S. Modrow. 1984. Secretion of gamma-interferon at the cellular level. Induction by Epstein-Barr virus. Scand. J. Immunol. 20:425-432.
6. Baldwin, A. S., Jr., and P. A. Sharp. 1987. Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene. Mol. Cell. Biol. 7:305-313.
7. Birkenbach, M., K. Josefsen, R. Yalamanchili, G. Lenoir, and E. Kieff. 1993. Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J. Virol. 67:2209-2220.
8. Birkenbach, M., D. Liebowitz, F. Wang, J. Sample, and E. Kieff. 1989. Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J. Virol. 63:4079-4084.
9. Bisotto, S., and E. D. Fixman. 2001. Src-family tyrosine kinases, phosphoinositide 3-kinase and Gab1 regulate extracellular signal-regulated kinase 1 activation induced by the type A endothelin-1 G-protein-coupled receptor. Biochem. J. 360:77-85.
10. Bonnefoy, J. Y., T. Defrance, C. Peronne, C. Menetrier, F. Rousset, J. Pene, J. E. De Vries, and J. Banchereau. 1988. Human recombinant interleukin 4 induces normal B cells to produce soluble CD23/IgE-binding factor analogous to that spontaneously released by lymphoblastoid B cell lines. Eur. J. Immunol. 18:117-122.
11. Brenner, V., G. Nyakatura, A. Rosenthal, and M. Platzer. 1997. Genomic organization of two novel genes on human Xq28: compact head to head arrangement of IDH gamma and TRAP delta is conserved in rat and mouse. Genomics 44:8-14.
12. Caldwell, R. G., J. B. Wilson, S. J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411.
13. Calender, A., M. Billaud, J. P. Aubry, J. Banchereau, M. Vuillaume, and G. M. Lenoir. 1987. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. USA 84:8060-8064.
14. Calender, A., M. Cordier, M. Billaud, and G. M. Lenoir. 1990. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int. J. Cancer 46:658-663.
15. Carbone, A., G. Gaidano, A. Gloghini, L. M. Larocca, D. Capello, V. Canzonieri, A. Antinori, U. Tirelli, B. Falini, and R. Dalla-Favera. 1998. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 91:747-755.
16. Carbone, A., G. Gaidano, A. Gloghini, C. Pastore, G. Saglio, U. Tirelli, R. Dalla-Favera, and B. Falini. 1997. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am. J. Pathol. 150: 155-165.
17. Citron, B. A., S. Kaufman, S. Milstien, E. W. Naylor, C. L. Greene, and M. D. Davis. 1993. Mutation in the 4a-carbinolamine dehydratase gene leads to mild hyperphenylalaninemia with defective cofactor metabolism. Am. J. Hum. Genet. 53:768-774.
18. Cohen, J. H., E. Fischer, M. D. Kazatchkine, G. M. Lenoir, C. Lefevre-Delvincourt, and J. P. Revillard. 1987. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. Scand. J. Immunol. 25:587-598.
19. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86:9558-9562.
20. Cordier, M., A. Calender, M. Billaud, U. Zimber, G. Rousselet, O. Pavlish, J. Banchereau, T. Tursz, G. Bornkamm, and G. M. Lenoir. 1990. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J. Virol. 64:1002-1013.
21. Dahl, C. A., R. P. Schall, H. L. He, and J. S. Cairns. 1992. Identification of a novel gene expressed in activated natural killer cells and T cells. J. Immunol. 148:597-603.
22. Davies, B., and M. Fried. 1993. The structure of the human intron-containing S8 ribosomal protein gene and determination of its chromosomal location at 1p32-p34.1. Genomics 15:68-75.
23. Delecluse, H. J., E. Kremmer, J. P. Rouault, C. Cour, G. Bornkamm, and F. Berger. 1995. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am. J. Pathol. 146:1113-1120.
24. Devergne, O., E. Cahir-McFarland, G. Mosialos, K. M. Izumi, C. F. Ware, and E. Kieff. 1998. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900-7908.
25. Ehlin-Henriksson, B., A. Manneborg-Sandlund, and G. Klein. 1987. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups. Int. J. Cancer 39:211-218.
26. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863-14868.
27. Eliopoulos, A. G., N. J. Gallagher, S. M. Blake, C. W. Dawson, and L. S. Young. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274:16085-16096.
28. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
29. Farrell, P. J., G. J. Allan, F. Shanahan, K. H. Vousden, and T. Crook. 1991. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:2879-2887.
30. Favrot, M. C., O. Maritaz, T. Suzuki, M. Cooper, I. Philip, T. Philip, and G. Lenoir. 1986. EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation. Int. J. Cancer 38:901-906.
31. Floettmann, J. E., and M. Rowe. 1997. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C terminus and requires oligomerisation for NF-κB activation. Oncogene 15:1851-1858.
32. Freemont, P. S., B. Dunbar, and L. A. Fothergill-Gilmore. 1988. The complete amino acid sequence of human skeletal-muscle fructose-bisphosphate aldolase. Biochem. J. 249:779-788.
33. Gaidano, G., A. Carbone, and R. Dalla-Favera. 1998. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J. Natl. Cancer Inst. Monogr. 23:95-100.
34. Gires, O., U. Zimber-Strobl, R. Gonnella, M. Ueffing, G. Marschall, R. Zeidler, D. Pich, and W. Hammerschmidt. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16:6131-6140.
35. Gregory, C. D., C. F. Edwards, A. Milner, J. Wiels, M. Lipinski, M. Rowe, T. Tursz, and A. B. Rickinson. 1988. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int. J. Cancer 42:213-220.
36. Grossman, S. R., E. Johannsen, X. Tong, R. Yalamanchili, and E. Kieff. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl. Acad. Sci. USA 91:7568-7572.
37. Hammarskjold, M. L., and M. C. Simurda. 1992. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66:6496-6501.
38. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:393-397.
39. Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol. 71:6611-6618.
40. Hart, T. C., P. S. Hart, D. W. Bowden, M. D. Michalec, S. A. Callison, S. J. Walker, Y. Zhang, and E. Firatli. 1999. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. J. Med. Genet. 36:881-887.
41. Hatzivassiliou, E., W. E. Miller, N. Raab-Traub, E. Kieff, and G. Mosialos. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160:1116-1121.
42. Henderson, A., S. Ripley, M. Heller, and E. Kieff. 1983. Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc. Natl. Acad. Sci. USA 80:1987-1991.
43. Henkel, T., P. D. Ling, S. D. Hayward, and M. G. Peterson. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science 265:92-95.
44. Honda, Y., J. Kondo, T. Maeda, Y. Yoshiyama, E. Yamada, Y. K. Shimizu, T. Shikata, and Y. Ono. 1990. Isolation and purification of a non-A, non-B hepatitis-associated microtubular aggregates protein. J. Gen. Virol. 71:1999-2004.
45. Hu, M. C., W. R. Qiu, X. Wang, C. F. Meyer, and T. H. Tan. 1996. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 10:2251-2264.
46. Huen, D. S., S. A. Henderson, D. Croom-Carter, and M. Rowe. 1995. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain. Oncogene 10:549-560.
47. Hurley, E. A., L. D. Klaman, S. Agger, J. B. Lawrence, and D. A. Thorley-Lawson. 1991. The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J. Virol. 65:3958-3963.
48. Hurley, E. A., and D. A. Thorley-Lawson. 1988. B cell activation and the establishment of Epstein-Barr virus latency. J. Exp. Med. 168:2059-2075.
49. Iyer, V. R., M. B. Eisen, D. T. Ross, G. Schuler, T. Moore, J. C. Lee, J. M. Trent, L. M. Staudt, J. Hudson, Jr., M. S. Boguski, D. Lashkari, D. Shalon, D. Botstein, and P. O. Brown. 1999. The transcriptional program in the response of human fibroblasts to serum. Science 283:83-87.
50. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 94:1447-1452.
51. Izumi, K. M., and E. D. Kieff. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. USA 94:12592-12597.
52. Johannes, G., M. S. Carter, M. B. Eisen, P. O. Brown, and P. Sarnow. 1999. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc. Natl. Acad. Sci. USA 96:13118-13123.
53. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and S. R. Grossman. 1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU.1. J. Virol. 69:253-262.
54. Johannsen, E., C. L. Miller, S. R. Grossman, and E. Kieff. 1996. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJκ in Epstein-Barr virus-transformed B lymphocytes. J. Virol. 70:4179-4183.
55. Kaiser, C., G. Laux, D. Eick, N. Jochner, G. W. Bornkamm, and B. Kempkes. 1999. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73:4481-4484.
56. Kanda, K., B. Kempkes, G. W. Bomkamm, A. von Gabain, and T. Decker. 1999. The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines. Biol. Chem. 380:213-221.
57. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
58. Khan, J., M. L. Bittner, L. H. Saal, U. Teichmann, D. O. Azorsa, G. C. Gooden, W. J. Pavan, J. M. Trent, and P. S. Meltzer. 1999. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. USA 96:13264-13269.
59. Kiefer, F., L. A. Tibbles, M. Anafi, A. Janssen, B. W. Zanke, N. Lassam, T. Pawson, J. R. Woodgett, and N. N. Iscove. 1996. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. EMBO J. 15:7013-7025.
60. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2511-2574. In D. Knipe, P. Howley, D. Griffin, M. Martin, R. Lamb, B. Roizman, and S. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
61. Kieser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478-6485.
62. Kim, H. S. 1999. Assignment of the human B3-1 gene (PSCDBP) to chromosome 2 band q11.2 by radiation hybrid mapping. Cytogenet. Cell Genet. 84:95.
63. King, W., A. L. Thomas-Powell, N. Raab-Traub, M. Hawke, and E. Kieff. 1980. Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J. Virol. 36:506-518.
64. Klaman, L. D., and D. A. Thorley-Lawson. 1995. Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-κB site. J. Virol. 69:871-881.
65. Knutson, J. C. 1990. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64:2530-2536.
66. Krauer, K. G., N. Kienzle, D. B. Young, and T. B. Sculley. 1996. Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-Jκ in B lymphocytes. Virology 226:346-353.
67. Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J. Biol. Chem. 267:24157-24160.
68. Lay, A. J., X. M. Jiang, O. Kisker, E. Flynn, A. Underwood, R. Condron, and P. J. Hogg. 2000. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408:869-873.
69. Lee, M. A., M. E. Diamond, and J. L. Yates. 1999. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J. Virol. 73:2974-2982.
70. Lewin, A. R., L. E. Reid, M. McMahon, G. R. Stark, and I. M. Kerr. 1991. Molecular analysis of a human interferon-inducible gene family. Eur. J. Biochem. 199:417-423.
71. Li, J., G. W. Peet, D. Balzarano, X. Li, P. Massa, R. W. Barton, and K. B. Marcu. 2001. Novel NEMO/IκB kinase and NF-κB target genes at the pre-B to immature B cell transition. J. Biol. Chem. 276:18579-18590.
72. Liebowitz, D., J. Mannick, K. Takada, and E. Kieff. 1992. Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J. Virol. 66:4612-4616.
73. Lin, J., E. Johannsen, E. Robertson, and E. Kieff. 2002. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol. 76:232-242.
74. Longnecker, R., C. L. Miller, X. Q. Miao, B. Tomkinson, and E. Kieff. 1993. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J. Virol. 67:2006-2013.
75. Lu, Y. J., D. Williamson, J. Clark, R. Wang, N. Tiffin, L. Skelton, T. Gordon, R. Williams, B. Allan, A. Jackman, C. Cooper, K. Pritchard-Jones, and J. Shipley. 2001. Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proc. Natl. Acad. Sci. USA 98:9197-9202.
76. Ludwig, J., S. Kerscher, U. Brandt, K. Pfeiffer, F. Getlawi, D. K. Apps, and H. Schagger. 1998. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J. Biol. Chem. 273:10939-10947.
77. Mannick, J. B., J. I. Cohen, M. Birkenbach, A. Marchini, and E. Kieff. 1991. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J. Virol. 65:6826-6837.
78. Matsumoto, R., H. Matsumoto, M. Seki, M. Hata, Y. Asano, S. Kanegasaki, R. L. Stevens, and M. Hirashima. 1998, Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273:16976-16984.
79. Mendel, D. B., P. A. Khavari, P. B. Conley, M. K. Graves, L. P. Hansen, A. Admon, and G. R. Crabtree. 1991. Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science 254:1762-1767.
80. Milburn, S. C., J. W. Hershey, M. V. Davies, K. Kelleher, and R. J. Kaufman. 1990. Cloning and expression of eukaryotic initiation factor 4B cDNA: sequence determination identifies a common RNA recognition motif. EMBO J. 9:2783-2790.
81. Miller, C. L., A. L. Burkhardt, J. H. Lee, B. Stealey, R. Longnecker, J. B. Bolen, and E. Kieff. 1995. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155-166.
82. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
83. Mosevitsky, M. I., J. P. Capony, G. Skladchikova, V. A. Novitskaya, A. Plekhanov, and V. V. Zakharov. 1997. The BASP1 family of myristoylated proteins abundant in axonal termini. Primary structure analysis and physico-chemical properties. Biochimie 79:373-384.
84. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. VanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399.
85. Muslin, A. J., J. W. Tanner, P. M. Allen, and A. S. Shaw. 1996. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84:889-897.
86. Nitsche, F., A. Bell, and A. Rickinson. 1997. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J. Virol. 71:6619-6628.
87. Oliva, D., L. Cali, S. Feo, and A. Giallongo. 1991. Complete structure of the human gene encoding neuron-specific enolase. Genomics 10:157-165.
88. Ounanian, A., B. Guilbert, and J. M. Seigneurin. 1992. Characteristics of Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease and age-matched controls. Mech. Ageing Dev. 63:105-116.
89. Park, S., Y. I. Kim, B. Kim, C. Seong, Y. Oh, K. Baek, and J. Yoon. 1998. Characterization of bovine and human cDNAs encoding NAP-22 (22 kDa neuronal tissue-enriched acidic protein) homologs. Mol. Cells 8:471-477.
90. Quintrell, N., R. Lebo, H. Varmus, J. M. Bishop, M. J. Pettenati, M. M. Le Beau, M. O. Diaz, and J. D. Rowley. 1987. Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Mol. Cell. Biol. 7:2267-2275.
91. Rickinson, A., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2628. In D. Knipe, P. Howley, D. Griffin, M. Martin, R. Lamb, B. Roizman, and S. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams and Wilkins, Philadelphia, Pa.
92. Robertson, E. S., S. Grossman, E. Johannsen, C. Miller, J. Lin, B. Tomkinson, and E. Kieff. 1995. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein Jκ. J. Virol. 69:3108-3116.
93. Robertson, E. S., B. Tomkinson, and E. Kieff. 1994. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J. Virol. 68:1449-1458.
94. Rodriguez, A. M., D. Rodin, H. Nomura, C. C. Morton, S. Weremowicz, and M. C. Schneider. 1997. Identification, localization, and expression of two novel human genes similar to deoxyribonuclease I. Genomics 42:507-513.
95. Rohan, P. J., P. Davis, C. A. Moskaluk, M. Kearns, H. Krutzsch, U. Siebenlist, and K. Kelly. 1993. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science 259:1763-1766.
96. Rowe, M., A. L. Lear, D. Croom-Carter, A. H. Davies, and A. B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
97. Sasaki, A., H. Yasukawa, A. Suzuki, S. Kamizono, T. Syoda, I. Kinjyo, M. Sasaki, J. A. Johnston, and A. Yoshimura. 1999. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4:339-351.
98. Schena, M., D. Shalon, R. W. Davis, and P. O. Brown. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470.
99. Semba, K., M. Nishizawa, N. Miyajima, M. C. Yoshida, J. Sukegawa, Y. Yamanashi, M. Sasaki, T. Yamamoto, and K. Toyoshima. 1986. yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proc. Natl. Acad. Sci. USA 83:5459-5463.
100. Shaffer, A. L., A. Rosenwald, E. M. Hurt, J. M. Giltnane, L. T. Lam, O. K. Pickeral, and L. M. Staudt. 2001. Signatures of the immune response. Immunity 15:375-385.
101. Spellman, P. T., G. Sherlock, M. Q. Zhang, V. R. Iyer, K. Anders, M. B. Eisen, P. O. Brown, D. Botstein, and B. Futcher. 1998. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol. Biol. Cell 9:3273-3297.
102. Sugden, B., and S. Metzenberg. 1983. Characterization of an antigen whose cell surface expression is induced by infection with Epstein-Barr virus. J. Virol. 46:800-807.
103. Swaminathan, S., B. Tomkinson, and E. Kieff. 1991. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc. Natl. Acad. Sci. USA 88:1546-1550.
104. Takahashi, K., N. Kitamura, T. Shibui, M. Kamizono, R. Matsui, Y. Yoshiyama, T. Maeda, J. Kondo, Y. Honda, E. Yamada, et al. 1990. Cloning, sequencing and expression in Escherichia coli of cDNA for a non-A, non-B hepatitis-associated microtubular aggregates protein. J. Gen. Virol. 71:2005-2011.
105. Takeshita, H., T. Yoshizaki, W. E. Miller, H. Sato, M. Furukawa, J. S. Pagano, and N. Raab-Traub. 1999. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol. 73:5548-5555.
106. Tang, H., T. Matthes, N. Carballido-Perrig, R. H. Zubler, and V. Kindler. 1993. Differential induction of T cell cytokine mRNA in Epstein-Barr virus-transformed B cell clones: constitutive and inducible expression of interleukin-4 mRNA. Eur. J. Immunol. 23:899-903.
107. Thorley-Lawson, D. A., L. M. Nadler, A. K. Bhan, and R. T. Schooley. 1985. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J. Immunol. 134:3007-3012.
108. Thorley-Lawson, D. A., R. T. Schooley, A. K. Bhan, and L. M. Nadler. 1982. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 30:415-425.
109. Tomkinson, B., and E. Kieff. 1992. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J. Virol. 66:2893-2903.
110. Tomkinson, B., E. Robertson, and E. Kieff. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67:2014-2025.
111. Torsteinsdottir, S., M. L. Andersson, J. Avila-Carino, B. Ehlin-Henriksson, M. G. Masucci, G. Klein, and E. Klein. 1989. Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int. J. Cancer. 43:273-278.
112. Turk, V., and W. Bode. 1991. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285:213-219.
113. Velazquez, L., M. Fellous, G. R. Stark, and S. Pellegrini. 1992. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70:313-322.
114. Waltzer, L., F. Logeat, C. Brou, A. Israel, A. Sergeant, and E. Manet. 1994. The human Jκ recombination signal sequence binding protein (RBP-Jκ) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 13:5633-5638.
115. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173-4184.
116. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309-2318.
117. Wang, F., C. D. Gregory, M. Rowe, A. B. Rickinson, D. Wang, M. Birkenbach, H. Kikutani, T. Kishimoto, and E. Kieff. 1987. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc. Natl. Acad. Sci. USA 84:3452-3456.
118. Ward, Y., S. Gupta, P. Jensen, M. Wartmann, R. J. Davis, and K. Kelly. 1994. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 367:651-654.
119. Yablonski, D., and A. Weiss. 2001. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv. Immunol. 79:93-128.
120. Yalamanchili, R., X. Tong, S. Grossman, E. Johannsen, G. Mosialos, and E. Kieff. 1994. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology 204:634-641.
121. Yokoyama, S., D. Staunton, R. Fisher, M. Amiot, J. J. Fortin, and L. D. Thorley. 1991. Expression of the Blast-1 activation/adhesion molecule and its identification as CD48. J. Immunol. 146:2192-2200.
122. Yu, J., C. Riou, D. Davidson, R. Minhas, J. D. Robson, M. Julius, R. Arnold, F. Kiefer, and A. Veillette. 2001. Synergistic regulation of immunoreceptor signaling by SLP-76-related adaptor Clnk and serine/threonine protein kinase HPK-1. Mol. Cell. Biol. 21:6102-6112.
123. Zeng, Z., D. Parmelee, H. Hyaw, T. A. Coleman, K. Su, J. Zhang, R. Gentz, S. Ruben, C. Rosen, and Y. Li. 1997. Cloning and characterization of a novel human DNase. Biochem. Biophys. Res. Commun. 231:499-504.
124. Zhao, B., D. R. Marshall, and C. E. Sample. 1996. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jκ. J. Virol. 70:4228-4236.
125. Zhu, H., J. P. Cong, and T. Shenk. 1997. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs. Proc. Natl. Acad. Sci. USA 94:13985-13990.
126. Ziegler, S. F., J. D. Marth, D. B. Lewis, and R. M. Perlmutter. 1987. Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin. Mol. Cell. Biol. 7:2276-2285.